$Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations$

Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations

Objective First, to investigate the overall efficacy and safety of rituximab (RTX) in refractory granulomatosis with polyangiitis (GPA) in a tertiary referral centre. Second, to compare the efficacy of RTX in granulomatous and vasculitic manifestations in GPA. Patients and methods This study compris...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2012-03, Vol.71 (3), p.327-333
Hauptverfasser:	Holle, Julia U, Dubrau, Christin, Herlyn, Karen, Heller, Martin, Ambrosch, Petra, Noelle, Bernhard, Reinhold-Keller, Eva, Gross, Wolfgang L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Murine-Derived - administration & dosage Antibodies, Monoclonal, Murine-Derived - adverse effects Antibodies, Monoclonal, Murine-Derived - therapeutic use Biological and medical sciences Biomarkers - blood Blood Sedimentation C-Reactive Protein - metabolism Diseases of the osteoarticular system Drug Administration Schedule Drug Evaluation Drug Therapy, Combination Female Granulomatosis with Polyangiitis - diagnosis Granulomatosis with Polyangiitis - drug therapy Humans Immunomodulators Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Infections Interdisciplinary aspects Male Medical sciences Middle Aged Pharmacology. Drug treatments Recurrence Retrospective Studies Rituximab Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Severity of Illness Index Studies Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!